市場調查報告書
商品編碼
1408047
全球重組蛋白市場評估:按產品、宿主細胞、應用、最終用戶、地區、機會、預測(2017-2031)Recombinant Proteins Market Assessment, By Product, By Host Cell, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球重組蛋白市場規模預計到2023年將達到25.1億美元,到2031年將達到64.7億美元,在2024-2031年預測期內複合年增長率為12.57%。 診斷和探索性研究領域的市場取得了顯著成長。 近年來到期的生物製品專利數量不斷增加,推動了市場需求。 預計 2022 年至 2027 年間,約 31 種生物製劑將失去獨佔權,創造龐大的市場需求。
生物技術領域不斷增加的研發支出正在推動全球重組蛋白市場的顯著成長。 由於重組蛋白在醫療、研究和生技領域的應用不斷擴大,預計在預測期內對重組蛋白產品的需求將會增加。 此外,癌症、自體免疫疾病和糖尿病等慢性病的盛行率不斷上升,需要生物製劑治療,約佔生物製劑市場的60%,重組蛋白市場的需求不斷增加,預計將吸引100%的公司。 然而,重組蛋白生產的特殊要求和產品的高成本是市場的限制因素。
越來越多的生物製品專利到期正在推動重組蛋白市場的成長。 生物製劑是由活細胞製成的複雜分子,用於治療多種疾病,包括癌症、自體免疫疾病和慢性腎臟病。 多個重磅生物製劑的專利已經到期或計劃到期,推動了生物相似藥和生物相似藥的發展。 這些專利的到期為生物相似藥和生物後續產品的開發創造了機會,推動了市場成長。
研發支出的增加對重組蛋白市場產生了重大影響。 增加的投資正在促進創新蛋白質體學和基因組學技術的發展,並促進重組蛋白的生產。 預計亞太地區研發活動的增加尤其明顯,為市場進入者提供潛在的成長機會。 研發支出的快速成長是市場擴張的關鍵驅動力。
由於細胞激素和生長因子在癌症、COVID-19、細胞培養、傳染病和傷口癒合研究中發揮重要作用,因此預計將佔據主導地位。 慢性病盛行率的增加和治療需求的增加增加了對重組蛋白產品的需求。 對這些因子的研究和開發正在推動細胞因子和生長因子領域的主導地位。
北美主導全球重組蛋白市場。 2022 年,北美將佔據大部分收入份額,並預計未來將保持這一地位。 該地區的優勢在於政府為製藥業的研發提供資助策略、增加研發項目以及有利的政府資助。 美國佔北美市場最大份額。 公司之間日益激烈的競爭和最終用戶的多樣化使用正在促進產品管道的擴展、新技術的開發和生物加工工具的進步。
全球重組蛋白市場前景廣闊,預計未來幾年將顯著成長。 市場驅動因素包括慢性病盛行率上升、研究和學術領域越來越多地採用生命科學和技術,以及領先的製藥和生物技術公司的大量存在。 由於研究活動、新產品開發和最終用戶採用率的增加,亞太地區預計將顯著成長。 預計該市場將由細胞激素、生長因子、抗體和免疫檢查點蛋白等產品主導。 該市場的主要參與者包括 Thermo Fisher Scientific, Inc.(美國)、R&D Systems(美國)、Abcam plc(英國)和 Merck KGaA(德國)。 除了醫學之外,重組蛋白還用於農業、食品生產和生物工程,預計在不久的將來需求將進一步增加。
本報告研究和分析了全球重組蛋白市場,提供市場規模和預測、市場動態、主要參與者現狀和前景等。
Global Recombinant Proteins market size was valued at USD 2.51 billion in 2023, and is expected to reach USD 6.47 billion in 2031, with a CAGR of 12.57% for the forecast period between 2024 and 2031F. The recombinant protein market has registered significant growth in the field of diagnostic and exploratory research. The increase in the number of biologics patents expiring recently is driving demand for the recombinant protein market. About 31 biologics will lose exclusivity between 2022 and 2027 which is expected to create huge demand in the market.
Increasing expenditure on research and development in the field of biotechnology is promoting significant growth in the global recombinant proteins market. Due to the expansion of applications of recombinant proteins in the domain of medicine, research, and biotechnology, the demand for recombinant protein products is expected to increase during the forecast period. Additionally, the growing prevalence of chronic diseases like cancer, auto-immune diseases, and diabetes require biologics for treatment and contribute to about 60% of the biologics market, which is expected to draw more business in the recombinant proteins market. However, specific requirements of recombinant protein production and high cost of products are some of the factors restraining recombinant proteins market.
For instance, in June 2022, Navigo Proteins GmbH, a leading provider of affinity ligands for customized chromatography solutions and protein engineering, developed an affinity resin to capture the glycoprotein gp64, an unwanted contaminant from the baculovirus insect cell production system. By effectively utilizing precision capturing technology, Navigo was able to create a Precision X ligand that binds to the gp64 contaminant.
The increasing number of biologics patent expiry is driving the growth of the recombinant proteins market. Biologics are complex molecules produced from living cells and are used to treat various diseases such as cancer, autoimmune diseases, and chronic kidney disease. Patents for several blockbuster biologics have expired or are set to expire, leading to the development of biosimilars and follow-on biologics. The expiration of these patents has created opportunities for the development of biosimilars and follow-on biologics, which are driving the growth of the recombinant proteins market.
According to The Center for Biosimilar, by 2023, patents on nearly 20 oncology biologics will expire. The highest-earning drug, Humira is losing exclusivity in the year 2023, opening a huge opportunity for the biosimilar market. Johnson & Johnson's Stelara is going off-patent in the second half of 2023 which is a promising candidate for the biosimilar market.
The increasing expenditure on research and development is significantly impacting the recombinant proteins market. The heightened investment is driving the development of innovative proteomic and genomic techniques, thereby fostering the production of recombinant proteins. The growing R&D initiatives are particularly notable in Asia-Pacific, which is expected to offer potential growth opportunities for market players. The surge in research and development spending is a key driver propelling the expansion of the recombinant proteins market. In February 2023, in a seed extension round, Canadian startup Future Fields secured USD 11.2 million to expand the use of fruit flies as high-value recombinant protein production machines. The firm aims to produce recombinant proteins at a large scale in 10,000 square feet of manufacturing space.
The cytokines and growth factors segment is expected to dominate due to its vast role in research in cancer, COVID-19, cell culture, infectious diseases, and wound healing. The increasing prevalence of chronic diseases and their growing treatment requirements has led to an increase in demand for recombinant protein products. Research and development around these factors are propelling the dominance of cytokines and growth factors segment. In September 2023, Sino Biological, Inc. launched several products for biological research including four high-quality recombinant cytokines and GMP grade cytokines.
North America dominates the global recombinant proteins market. In 2022, North America accounted for a significant portion of the revenue share, and it is expected to maintain its position in the coming years. The region's dominance can be attributed to the availability of funding government initiatives for R&D in the pharmaceutical industry, more R&D programs, and a favorable funding from the government. The United States accounted for the largest share in the North America recombinant proteins market. The growth in competition among players and diverse applications by end-users has contributed to the expansion of product pipelines, the development of new technologies, and the advancement of bioprocessing tools.
The outlook for the global recombinant proteins market appears to be promising, with significant growth expected in the coming years. The market is driven by factors such as the rising prevalence of chronic diseases, the growing adoption of life science techniques in research and academia, and the huge presence of major pharmaceutical and biotechnology companies. Asia-Pacific is projected to witness significant growth due to increasing research activities, new product development, and expanding applications by end-users. The market for recombinant proteins is expected to be dominated by products such as cytokines, growth factors, antibodies, and immune checkpoint proteins. Key players in the recombinant proteins market include Thermo Fisher Scientific, Inc. (US), R&D Systems (US), Abcam plc (UK), Merck KGaA (Germany), and others. Apart from healthcare, recombinant proteins are used in agriculture, food production, and bioengineering, which is further expected to increase demand in the near future.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of strategies. To gain market share, companies are expanding the range of products they offer. Industry participants use a variety of growth methods, including collaborations, mergers and acquisitions, product launches, and the development of new goods, to bolster their position in the market.
In January 2022, Thermo Fisher Scientific Inc. completed the acquisition of PeproTech, Inc. for a total cash purchase price of approximately USD 1.85 billion. PeproTech was a leading manufacturer of recombinant proteins in the United States. The acquisition strengthened the recombinant portfolio of Thermo Fisher Scientific.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.